More Than Two-Thirds Of Listed Pharma In China Reports Q1-3 Sales Growth
This article was originally published in PharmAsia News
Among the 113 listed pharma in China, more than two thirds reported sales growth in the first three quarters of the year.
You may also be interested in...
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.